8-K: Profusa Licenses Mayo Clinic Oxygen Monitoring Tech

Profusa, Inc. has entered into an exclusive know-how license agreement with Mayo Foundation for Medical Education and Research for continuous oxygen measurement tools and Critical Limb-Threatening Ischemia applications.

Summary

• Profusa, Inc. entered into a know-how license agreement with Mayo Foundation for Medical Education and Research on February 11, 2026.
• The agreement grants Profusa an exclusive, worldwide license to certain patent rights and a non-exclusive license to related know-how in the fields of continuous oxygen measurement tools and Critical Limb-Threatening Ischemia (CLTI).
• This includes use with Profusa's Lumee product and future versions, aiming to accelerate regulatory approval and commercialization for CLTI in the U.S.
• The collaboration will also investigate high-impact clinical applications for new product development in areas like cardiovascular, renal, multi-organ, and orthopedic applications.
• Financial terms include royalties on net sales of licensed products, milestone payments upon achieving development and commercialization events, and a share of sublicense income.
• Mayo will provide reasonable access to its investigators for know-how transfer for a period of [***] following the effective date.
• Profusa is required to make commercially reasonable efforts to bring Licensed Products to market and provide annual diligence reports.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it secures key intellectual property and clinical collaboration with a reputable institution, enhancing Profusa's commercialization prospects, despite the financial terms being partially redacted.

Positives

• Secures exclusive worldwide license to Mayo's patent rights and non-exclusive license to related know-how for continuous oxygen measurement and CLTI.
• Leverages Mayo Clinic's expertise and reputation, potentially accelerating regulatory approval and commercialization of the Lumee product.
• Expands potential market and therapeutic reach by investigating new high-impact clinical applications (cardiovascular, renal, multi-organ, orthopedic).
• Mayo Clinic investigators will provide reasonable access for know-how transfer, facilitating product development.
• The license becomes fully paid-up after the term if Profusa meets its obligations, providing long-term intellectual property rights.

Negatives

• Significant financial obligations including undisclosed royalty percentages on net sales, undisclosed milestone payments, and [***]% of sublicense income.
• Sublicensing requires Mayo's prior written approval and adherence to specific conditions, potentially limiting flexibility.
• Profusa is responsible for all costs and expenses associated with filing, prosecution, and maintenance of Foreground Patent Rights.
• Profusa must indemnify Mayo for claims arising from the agreement or Licensed Products, except for Mayo's gross negligence or intentional misconduct.
• The duration of Mayo Investigator access for know-how transfer is redacted ([***]), making the extent of direct support unclear.

Risks

• Commercialization risk: Profusa must make commercially reasonable efforts to bring Licensed Products to market, which may not be successful.
• Regulatory risk: Achieving regulatory clearances or approvals for Licensed Products is necessary for commercial sale and is not guaranteed.
• Financial burden: Significant financial commitments (royalties, milestones, sublicense income share, IP costs, insurance) could strain resources if commercialization is slow or unsuccessful.
• Dependence on Mayo's IP: The license is crucial for product development and commercialization; any issues with the underlying patent rights or know-how could impact Profusa.
• Sublicensing limitations: Restrictions on sublicensing (prior approval, specific terms) could hinder strategic partnerships or monetization efforts.
• Litigation risk: Company indemnifies Mayo for claims related to Licensed Products, exposing Profusa to potential legal costs.
• Competition: The market for continuous oxygen monitoring and CLTI solutions may be competitive, impacting market penetration and sales.

Future Outlook

Profusa aims to accelerate regulatory approval and commercialization of its Lumee oxygen sensing and tissue monitoring technology for critical limb ischemia in the U.S. The company also seeks to develop and commercialize new tethered continuous oxygen monitoring products for high-impact clinical applications, including cardiovascular, renal, multi-organ, and orthopedic uses, to address unmet clinical needs and reduce healthcare costs through earlier detection and improved disease management.

Management Comments

• "Oxygen is essential for cellular metabolism and tissue repair, with lack of sufficient oxygenation impairing wound healing, increasing risk of infection, and contributing to complications common to surgery, such as leakage and anastomotic structure." Michael Kendrick, M.D., Chair of Department of Surgery at Mayo Clinic.
• "Our collaboration gives us the opportunity to leverage their innovative platform to potentially address unmet clinical challenges, including the ability to monitor beyond subcutaneous tissue." Michael Kendrick, M.D., Chair of Department of Surgery at Mayo Clinic.
• "Following more than a decade of development and over $100 million in investment, our Lumee technology enables continuous, real-time measurement of tissue oxygen directly within the body, which we believe to be a first-of-its-kind, disruptive biochemistry monitoring platform." Ben Hwang, Ph.D., Profusa's Chairman and CEO.
• "We are committed to continue to harness our platform technology for innovative solutions that seek to both address large unmet clinical needs and reduce costs for healthcare systems through earlier detection and improved disease management." Ben Hwang, Ph.D., Profusa's Chairman and CEO.
• "We look forward to collaborating with Mayo Clinic for the U.S. commercialization of Lumee for critical limb ischemia, and developing products to address new indications to expand our oxygen tissue monitoring technology’s market and therapeutic reach." Ben Hwang, Ph.D., Profusa's Chairman and CEO.

Industry Context

StockSavvy.ai notes that this collaboration positions Profusa to potentially gain significant traction in the rapidly evolving digital health and medical device sectors, particularly in continuous monitoring technologies. The partnership with a renowned institution like Mayo Clinic lends considerable credibility and access to clinical expertise, which is crucial for validating and commercializing innovative medical technologies. The focus on critical limb-threatening ischemia and other high-impact applications aligns with a growing demand for advanced diagnostic and monitoring tools that can improve patient outcomes and reduce healthcare costs.

Comparison to Industry Standards

• The Lumee technology, described as a "first-of-its-kind, disruptive biochemistry monitoring platform" for continuous, real-time tissue oxygen measurement, suggests a potential competitive advantage over existing intermittent or less precise oxygen monitoring methods.
• While specific comparable companies or projects are not detailed in the filing, the collaboration with Mayo Clinic, a leading medical institution, implies a high standard of clinical validation and potential for broad adoption, similar to partnerships seen with other innovative medical technology firms seeking to integrate into established healthcare systems.
• The stated goal of addressing large unmet clinical needs and reducing healthcare costs through earlier detection and improved disease management aligns with broader industry trends and benchmarks for successful medical technology innovation.

Related Party Transactions

• Mayo Clinic has a financial interest in the technology referenced in the press release.
• Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.

Stakeholder Impact

• Shareholders: Potential for increased value through accelerated product development, commercialization, and market expansion, but also subject to financial obligations and commercialization risks.
• Customers/Patients: Potential for improved clinical outcomes and disease management through new continuous oxygen monitoring tools, particularly for critical limb-threatening ischemia and other high-impact applications.
• Employees: Potential for increased job security and growth opportunities due to expanded product pipeline and market reach.
• Creditors: Financial obligations (royalties, milestones) could impact cash flow, but successful commercialization could improve financial stability.

Next Steps

• Profusa to make commercially reasonable efforts to bring Licensed Products to market in the Field.
• Mayo to provide reasonable access to Mayo Investigator(s) for know-how transfer for a period of [***] following the Effective Date.
• Profusa to provide Mayo with annual diligence reports within [***] days of each anniversary of the Effective Date, detailing development and marketing activities and an updated development plan.
• Profusa to provide regular royalty reports and maintain records subject to audit.
• Profusa to pursue regulatory clearances or approvals for Licensed Products to enable commercial sale.

Key Dates

Recommendation

The licensing agreement with Mayo Clinic is a significant positive step, providing access to valuable know-how and clinical expertise, which could accelerate the commercialization of Profusa's Lumee technology and expand its market reach. However, the financial terms, including royalty percentages and milestone payments, are redacted, making a full quantitative assessment of the deal's impact on profitability difficult. While the partnership offers strong potential, the inherent risks of medical device development, regulatory approvals, and market adoption remain. Given the redacted financial details and the long-term nature of product development, a "hold" recommendation is appropriate, advising investors to monitor progress on commercialization and future financial disclosures.

Keywords

Profusa, Mayo Clinic, Know-How License Agreement, Oxygen Monitoring, Critical Limb-Threatening Ischemia, CLTI, Lumee, Digital Health, Biosensors, Medical Devices, Patent Rights, Commercialization, Regulatory Approval, Healthcare Technology